Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 17Docetaxel 13Specimen Handling 12Radiotherapy 11Surveys and Questionnaires 10Cyclophosphamide 10Blood Specimen Collection 9Radiosurgery 8Paclitaxel 8Gemcitabine 8Drug Therapy 8sargramostim 7Trastuzumab 7Nivolumab 7Carboplatin 7Injections 6Early Intervention, Educational 6Taxes 5Psychiatric Rehabilitation 5Methods 5Interviews as Topic 5Educational Status 5spartalizumab 4motexafin gadolinium 4aldesleukin 4X-Rays 4Therapeutics 4Standard of Care 4Spinal Puncture 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × parsaclisib × Breast × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡